LRP1B突变与子宫内膜癌的淋巴结转移有关:一项临床下一代测序研究
Yunfeng Zheng1, Fan Yang2, Jie Wu3
1Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
The International journal of biological markers
|December 17, 2024
概括
低密度脂蛋白受体相关蛋白1B (LRP1B) 突变与子宫内膜癌中淋巴结转移 (LNM) 的减少有关. LRP1B突变状态可以预测LNM,有助于预防和治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 子宫内膜癌是一种显著的妇科恶性瘤.
- 淋巴结转移 (LNM) 是子宫内膜癌的关键预后因素.
- 低密度脂蛋白受体相关蛋白1B (LRP1B) 在子宫内膜癌进展中的作用,特别是LNM,需要进一步调查.
研究的目的:
- 研究LRP1B在子宫内膜癌中的突变状态和蛋白质表达.
- 分析LRP1B变化与淋巴结转移 (LNM) 之间的关联.
- 评估LRP1B突变作为LNM在子宫内膜癌的潜在预测因子.
主要方法:
- 从94名子宫内膜癌患者的瘤组织和配对血液DNA上进行了针对性的下一代测序 (NGS).
- 免疫组织化学 (IHC) 来评估LRP1B蛋白表达.
- 统计分析包括多变量分析和预测值的AUC计算.
主要成果:
- 在20.2%的患者中发现了LRP1B突变.
- 在患有和没有LNM的患者之间,LRP1B突变频率显著不同 (P=0.038).
- LRP1B突变是减少LNM (OR=0.09,P=0.045) 的有利预测因子,综合分析得出AUC为0.871.1.
结论:
- LRP1B突变与子宫内膜癌中淋巴结转移的风险较低有关.
- 结合临床变异的LRP1B突变状态,可以改善LNM预测.
- 这些发现支持基于LRP1B状态开发针对子宫内膜癌的向预防和治疗策略.
相关概念视频
03:18Non-LTR Retrotransposons
11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K